Nuala Brennan

Technik-/Wissenschafts-/F&E-Leiter bei MOONLAKE IMMUNOTHERAPEUTICS

55 Jahre

Health Technology

Consumer Services

Aktive Positionen von Nuala Brennan

Unternehmen	Position	Beginn	Ende
MOONLAKE IMMUNOTHERAPEUTICS	Technik-/Wissenschafts-/F&E-Leiter	01.09.2021	-
Moonlake Immunotherapeutics Ltd.	Technik-/Wissenschafts-/F&E-Leiter	01.09.2021	-

Unternehmen	Position	Beginn	Ende
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Technik-/Wissenschafts-/F&E-Leiter	01.04.2016	01.08.2021

University of Leicester

Undergraduate Degree

International

Vereinigtes Königreich	4
Schweiz	2

Operativ

Chief Tech/Sci/R&D Officer	3
Undergraduate Degree	1

Sektoral

Health Technology	3
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
MOONLAKE IMMUNOTHERAPEUTICS	Health Technology

Private Unternehmen	2
Moonlake Immunotherapeutics Ltd.
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Health Technology

Private Unternehmen

Moonlake Immunotherapeutics Ltd.

Health Technology